Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEMPO: TMP-SMX Effects on Nasal Microbiome in GPA
NCT03919435Phase 2Active, not recruiting
- Sponsor
- University of Pennsylvania
- Start
- Mar 2019
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trimethoprim + sulfamethoxazole in granulomatosis with polyangiitis (GPA), sponsored by University of Pennsylvania. Primary endpoint: Nasal microbiome in relative abundance (host gene expression in proportion) at 24 weeks. Started Mar 2019; status: active, not recruiting.
02
Drugs
trimethoprim + sulfamethoxazole
03
Conditions
granulomatosis with polyangiitis (GPA)
Beyond the preview
Go deeper on NCT03919435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03919435.